Background {#s1}
==========

Essential hypertension (HT) is one of the leading causes of preventable deaths and a major risk factor for serious disorders such as coronary heart disease, heart failure, peripheral vascular disease, renal failure and stroke. Pathogenesis of HT is multifactorial and synthesis and/or release of nitric oxide (NO), which regulates local blood flow and modulates sodium reabsorption, plays a role in this process.

In order to shed light on the multifactorial pathophysiological mechanisms of hypertension and to improve preventative and therapeutic strategies, many experimental models have been used. One of these experimental models is impairment of NO production in the blood vessel layer, which is a major pathway for the development of hypertension, by using nitric oxide synthase (NOS) inhibitors.[@R01],[@R02]

Acute or chronic inhibition of NO production by NOS inhibitors causes hypertension,[@R03]-[@R07] and the degree of elevation of blood pressure is dose and time dependent. With total inhibition of NOS with high doses, increased periferal resistance comes to the fore as the underlying cause; however, water and salt retention, activation of the symphathetic system and oxidative stress are important contributors.[@R08]-[@R10]

Oxidative stress was shown to be related to inadequate natriuresis and vasodilatation by means of impaired expression or function of renal dopaminergic receptors, however the mechanism is not clear.[@R11] The exact role of oxidative stress in the development of HT via NOS inhibition and the regulatory effect of the anti-oxidant system in this process remains unresolved.

Resveratrol (3,4′,5-trihydroxy-trans-stilbene) (RSV) is a type of natural phenol found in red grapes, peanuts, red wine and other polyphenol-rich food. Anti-proliferative,[@R03],[@R04] anti-inflammatory,[@R05] anti-oxidant[@R05]-[@R07],[@R12]-[@R14] and cardioprotective[@R15] effects of resveratrol have been shown in different experimental models so far.

Human studies established that acute administration of RSV generated dose-dependent improvement of endotheliumdependent vasodilatation.[@R16] Aminopiridin-sensitive potassium channels play a role in that process and a potassium-independent pathway (propably related to voltage-dependent calcium channels) is also thought to be responsible for the vasodilatory efects of RSV.[@R17],[@R18] Furthermore, it was shown that aortic vasodilation, with a low dose of RSV, was generated via the endothelial NOS effect.[@R19]

In our study, we aimed to investigate the effect of resveratrol on blood pressure in rats that become hypertensive via NOS inhibition with the application of L-NNA in doses that cause mild hypertension.[@R20] Changes in parameters related to water--salt balance and renal functions were also analysed.

Methods {#s2}
=======

Male Sprague-Dawley rats (230--260 g) from Harlan were housed under standard conditions with a 12-hour light--dark cycle in standard cages in a room with a controlled humidity of 40% and a temperature of 22°C. They had ad libitum access to food and water for 10 days.

Experimental procedures were in agreement with institutional and legislator regulations and approved by the local ethics committee for animal experimentation.

The rats (n = 35) were randomly divided into five groups (n = 7 in each group): control \[intraperitoneal (i.p.) 1 ml 0.9% serum physiological solution applied for 10 days\], L-NNA (15 mg/100 ml L-NNA given with drinking water for 10 days), RSV-E \[1 ml resveratrol eluent (20% ethanol) i.p. applied for 10 days\], RSV50 (50 mg/kg resveratrol i.p. applied for 10 days) and L-NNA + RSV50 (15 mg/100 ml L-NNA given with drinking water and 50 mg/kg resveratrol i.p. applied for 10 days).

The amount of consumed water was quantified every day and all applications were performed at the same time of day. The dose of L-NNA was calculated from the amount of consumed water and the drinking water of all groups was refreshed every day.

Each subject was placed in a separate box in a quiet area. Atail-cuff pletysmograph (MAY BPHR 9610-PC TAIL-CUFF Indirect Blood Pressure Recorder, Ankara, Turkey) and its sensor were fixed to their tails, which were warmed up to 37--38°C for 10--20 minutes, until it picked up regular signals and obtained pulses. Systolic blood pressure and heart rate were measured with the indirect tail-cuff method on the first, seventh and 10th days of the study by investigators who were blinded to the study protocol. An average of three measurements was recorded on each occasion.

All rats were put into metabolic cages at the end of study protocol. The total water intake and urine output were determined for 24 hours. We added 0.1 ml 6N HCl to the urine containers and kept the samples in the dark. Urine samples were put into Eppendorf tubes and stored at --80°C (Sanyo Ultra Low Temperature Freezer MDF-U4086S).

At the end of the experiment, the animals were anesthetised with 20% urethane (1 g/kg, i.p.). Blood samples were collected by heart puncture, and serum samples were obtained after centrifugation of the blood at 5 400 rpm for 10 minutes and stored at --80°C. We measured urea, creatinine and sodium levels in the blood and urine samples with a Roche Cobas 6000 autoanalyser (Mannheim, Germany).

Fluid balance, sodium clearance rate (CNa), glomerular filtration rate (GFR) and fractional sodium excretion (%FENa) were calculated using the following formulae:

Fluid balance = water intake -- urine volume

C~Na~ = (urine sodium x UFR) / plasma sodium

GFR = (urine creatinine x plasma creatinine) / UFR

%FE~Na~ (plasma creatinine x urine sodium) / (plasma sodium x urine creatinine) x 100

Statistical analysis {#s3}
====================

All statistical analyses were performed with IBM SPSS Statistics 16 software (SPSS Inc, Chicago, IL, USA). Data are expressed as mean ± standard error. Blood pressure values were compared with the Student's t-test and biochemical values via one-way analysis of varience (ANOVA) with post hoc Bonferroni comparison. All p-values were two-tailed and p \< 0.05 was considered to be statistically significant.

Results {#s4}
=======

The body weight gains of all groups were similar and are shown in [Table 1](#T1){ref-type="table"}. The first measured blood pressure values (before the protocol) were similar between the groups ([Table 2](#T2){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}). At the end of the study protocol, blood pressures were higher in the L-NNA (117.8 ± 3.5 vs 149.5 ± 2.1 mmHg; p \< 0.05) and L-NNA + RSV50 (122.8 ± 7.3 vs 155.4 ± 4.4 mmHg; p \< 0.05) groups ([Table 2](#T2){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}).

###### Weight gain in the study groups

  *Groups (n = 7)*   *First day (g)*   *Last day (g)*
  ------------------ ----------------- ----------------
  Control            154 ± 5.5         199.4 ± 7.2
  L-NNA              155 ± 3.3         209.0 ± 3.3
  RSV50              151 ± 2.8         188.5 ± 4.2
  RSV-E              188 ± 5.6         214.8 ± 16.9
  L-NNA + RSV50      186 ± 6.3         194.3 ± 5.2

###### Blood pressure measurements of the study groups at the beginning and end of the study

  *Groups (n = 7)*   *First measured (mmHg)*   *Last measured (mmHg)*
  ------------------ ------------------------- ------------------------
  Control            123.1 ± 5.5               121.1 ± 3.5
  L-NNA              117.8 ± 3.5               149.5 ± 2.1\*^βγ^
  RSV50              122.4 ± 3.8               124.2 ± 2.4
  RSV-E              126.6 ± 6.4               121.7 ± 7.8
  L-NNA + RSV50      122.8 ± 7.3               155.4 ± 4.4\*^βγ^

\*Compared to the control group, p \< 0.05; βcompared to the RSV50 group, p \< 0.05; γcompared to the RSV-E group, p \< 0.05.

![The first and the last measured blood pressures of the study groups.](cvja-28-143-g001){#F1}

L-NNA (42.0 ± 1.0) and RSV (44.7 ± 3.6 ml) application did not alter the water intake, whereas it was found to be significantly lower in the L-NNA + RSV50 (25.9 ± 2.9 ml) and RSV-E (26.8 ± 4.3 ml) groups compared to the control group (33.7 ± 4.1 ml) ([Table 3](#T3){ref-type="table"}).

###### Water intake, urine volume and water balance in the study groups

  *Groups (n = 7)*   *Water intake (ml)*   *Urine volume (ml)*   *Water balance (ml)*
  ------------------ --------------------- --------------------- ----------------------
  Control            33.7 ± 4.1            11.6 ± 1.2            2 2.1 ± 4.1
  L-NNA              42 ± 1.0              14 ± 0.5              28.0 ± 1.0
  RSV50              44.7 ± 3.6            10.1 ± 0.3^αγ^        34.6 ± 3.5\*
  RSV-E              26.8 ± 4.3^αβ^        3.3 ± 1.1\*^αβ^       23.5 ± 3.7
  L-NNA + RSV50      25.9 ± 2.9^αβ^        12.9 ± 1.2\*          13 ± 2.4^αβ^

\*Compared to the control group, p \< 0.05; αcompared to the L-NNA group, p \< 0.05; βcompared to the RSV50 group, p \< 0.05; γcompared to the RSV-E group, p \< 0.05.

Compared to the control group (11.6 ± 1.2 ml), urine volume did not change in the L-NNA (14.0 ± 0.5 ml), RSV50 (10.1 ± 0.3 ml) and L-NNA + RSV50 (12.9 ± 1.2 ml) groups. However, interestingly, urine volume (3.3 ± 1.1 ml) as well as water intake was significantly lower in the RSV-E group ([Table 3](#T3){ref-type="table"}).

Although the application of RSV with L-NNA decreased the fluid balance (13.0 ± 2.4 ml), RSV application alone increased it (34.6 ± 3.5 ml). L-NNA application alone did not alter (28.0 ± 1.0 ml) the fluid balance compared to the control group (22.0 ± 4.0 ml) ([Table 3](#T3){ref-type="table"}, [Fig. 2](#F2){ref-type="fig"}).

![Fluid balances of the study groups.](cvja-28-143-g002){#F2}

Serum and urine sodium concentrations ([Table 4](#T4){ref-type="table"}) and urea and creatinine ([Table 5](#T5){ref-type="table"}) levels were similiar between the groups. Applications did not alter the values measured at the end of the study compared with those measured at the beginning of the protocol (data not shown).

###### Serum sodium concentrations and 24-hour urine samples

  *Groups (n = 7)*   *Serum Na (mEq/l)*   *24-hour urine Na (mEq/l)*
  ------------------ -------------------- ----------------------------
  Control            144.0 ± 0.53         0.84 ± 0.11
  L-NNA              143.4 ± 0.4          0.72 ± 0.07
  RSV50              143.7 ± 0.5          0.86 ± 0.14
  RSV-E              143.5 ± 0.4          0.84 ± 0.15
  L-NNA + RSV50      143.2 ± 0.4          0.89 ± 0.16

###### Creatinine and urea levels in serum and 24-hour urine samples

  *Groups (n = 7)*   *Serum creatinine (mg/dl)*   *Serum urea (mg/dl)*   *24-hour urine creatinine (mg/dl)*   *Control*
  ------------------ ---------------------------- ---------------------- ------------------------------------ -------------
  Control            0.38 ± 0.01                  44.60 ± 2.63           57.03 ± 2.81                         0.58 ± 0.03
  L-NNA              0.36 ± 0.02                  48.67 ± 2.74           52.60 ± 4.15                         0.47 ± 0.05
  RSV50              0.39 ± 0.03                  40.31 ± 2.96           52.21 ± 2.86                         0.48 ± 0.04
  RSV-E              0.37 ± 0.02                  43.65 ± 3.77           53.58 ± 3.38                         0.55 ± 0.03
  L-NNA + RSV50      0.38 ± 0.01                  44.09 ± 0.73           58.44 ± 3.60                         0.56 ± 0.01

RSV and L-NNA application alone did not alter CNa, however it was lower in the RSV-E (0.0015 ± 0.0007 ml/min) group compared to both the RSV50 (0.0042 ± 0.0007 ml/min) and L-NNA (0.0055 ± 0.0011 ml/min) groups ([Table 6](#T6){ref-type="table"}, [Fig. 3](#F3){ref-type="fig"}).

###### Sodium clearance rate (CNa), glomerular filtration rate (GFR) and fractional sodium excretion (%FENa) values

  *Groups (n = 7)*   *C~Na~ (ml/min)*     *GFR (ml/min)*     *%FE~Na~*
  ------------------ -------------------- ------------------ -------------
  Control            0.0047 ± 0.0007^γ^   1.25 ± 0.19^γ^     0.38 ± 0.04
  L-NNA              0.0049 ± 0.0005^γ^   1.30 ± 0.16^γβ^    0.42 ± 0.07
  RSV50              0.0042 ± 0.0007^γ^   0.87 ± 0.08^γ^     0.53 ± 0.11
  RSV-E              0.0015 ± 0.0007      0.32 ± 0.09^\*β^   0.41 ± 0.09
  L-NNA + RSV50      0.0055 ± 0.001^γ^    1.33 ± 0.14^γβ^    0.42 ± 0.08

\*Compared to the control group, p \< 0.05; αcompared to the L-NNA group, p \< 0.05; βcompared to the RSV50 group, p \< 0.05; γcompared to the RSV-E group, p \< 0.05.

![Sodium clearance values of the study groups.](cvja-28-144-g003){#F3}

GFR was significantly lower in the RSV-E group (0.32 ± 0.09 ml/min) compared to the other groups and it was also lower in the RSV50 group (0.87 ± 0.08 ml/min) compared to the L-NNA (1.30 ± 0.16 ml/min) and the L-NNA + RSV50 (1.33 ± 0.14 ml/min) groups ([Table 6](#T6){ref-type="table"}, [Fig. 4](#F4){ref-type="fig"}).

![Glomerular filtration rates of the study groups.](cvja-28-144-g004){#F4}

Fractional sodium excretion values were similar in all groups ([Table 6](#T6){ref-type="table"}, [Fig. 5](#F5){ref-type="fig"}).

![Fractional sodium excretion values of the study groups.](cvja-28-144-g005){#F5}

Discussion {#s5}
==========

It has been demonstrated that vascular oxidative stress plays an important role in the pathogenesis of essential hypertension,[@R21] and many experimental studies have been published using anti-oxidants to prevent the development of hypertension or to decrease blood pressure. Hu et al.[@R22] showed that apocynin \[a nicotinamide dinucleotide phosphate (NADPH) oxidase inhibitor\] application prevented and reversed dexamethasoneinduced (via NADPH oxidase-mediated superoxide production) hypertension in rats. Another study revealed that tempol \[a superoxide dismutase (SOD) mimetic\] application decreased blood pressure and renal vascular resistance in spontaneously hypertensive rats by eliminating unfavourable peroxynitrite formation from the superoxide by competition with NO.[@R23]

We aimed to investigate the effects of RSV in preventing the development of hypertension, which was induced by NOS inhibition. RSV application alone did not alter blood pressure in the normotensive rats. Application of RSV plus L-NNA did not reverse the blood pressure increase induced by L-NNA. This may have been related to the dose of RSV or the length of the application period. Various protocols have been used in other studies.

Bhatt et al.[@R24] gave RSV dissolved in drinking water to rats at a concentration of 50 mg/l for 10 weeks and revealed that the development of hypertension was attenuated in the spontaneously hypertensive rats. Gordish et al.[@R25] administered RSV at a dose of 5 mg/kg to rats via the femoral vein and proved that the acute renal vasodilatory effect of RSV was mediated by increased NO production/bioavailability and its superoxidescavenging effect. We did not measure oxidative stress markers such as malondialdehyde (MDA), however we possibly achieved sufficient antioxidant effect by the RSV aplications.

In addition, it was shown that abnormalities in vascular NO production and transport resulted in hypertension due to endothelial dysfunction. RSV increased NO synthesis and functioned as a potent in vivo anti-oxidant.[@R26]

Interestingly, in the RSV50 group, the water balance was significantly higher compared to the control group despite no significant changes in water intake and urine output. Application of L-NNA plus RSV decreased the water balance compared to the application of RSV only, however it was not significantly different compared to the control group. Decreased urine volume may have been related to diminished water intake, as found in previous studies.[@R27]-[@R29]

C~Na~ and GFR values were lower in the RSV-E group and these findings were attributed to the RSV eluent (20% ethanol), which is comparable with the study of Barrero and co-workers.[@R30] They showed that creatinine and sodium clearance decreased after ethanol application in rats.

The kidneys play a critical role in long-term control of blood pressure. Reduction in renal sodium excretion or a rightward shift in the pressure--natriuresis relationship results in persistent hypertension, and NO plays an important role in this process by regulating the renal response to changes in perfusion pressures. Suprisingly, renal functional parameters were not affected by NOS inhibition in our study.

Tolins et al.[@R31] revealed that renal and systemic vascular resistance increased, and renal blood flow and sodium excretion were decreased by NOS inhibition. Griffin et al.[@R32] showed that Sprague-Dawley rats from Harlan, which exhibited the expected hypertension, proteinuria and glomerular damage, and those from Charles River, which showed a blunted increase in blood pressure and a resistance to nephropathy, exhibited largedifferences in susceptibility to nephropathy by L-NAME-induced NOS inhibition over a period of four weeks. We used L-NNA instead of L-NAME for NOS inhibition in order to obtain earlier blood pressure increase, and we evaluated fluid balance, CNa, GFR and %FENa but not proteinuria and morphological parameters of renal damage over a period of 10 days.

Conclusion {#s6}
==========

Although it is a potent anti-oxidant and inceases NO production/bioavailibilty, resveratrol was incapable of preventing the development of hypertension or reversing the blood pressure increase in L-NNA-induced hypertension models in our study. We cannot generalise this finding, as resveratrol is not a good candidate for the treatment of hypertension developed via the NOS-inhibition pathway. We suggest that further studies are needed to assess this hypothesis, with higher doses and/or longer periods of time.
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